-
Australia
-
Austria
-
Belgium
-
Brazil
-
Canada
-
China
-
Czech Republic
-
Denmark
-
Finland
-
France
-
Germany
-
Greece
-
Hong Kong
-
Hungary
-
Iceland
-
India
-
Ireland
-
Israel
-
Italy
-
Japan
-
Korea
-
Luxembourg
-
Malaysia
-
Netherlands
-
New Zealand
-
Norway
-
Poland
-
Qatar
-
Romania
-
Saudi Arabia
-
Singapore
-
Spain
-
Sweden
-
Switzerland
-
Taiwan
-
Turkey
-
United Kingdom
-
United States
RIP kinase Inhibitors
| Cat.No. | Product Name | Information | Product Use Citations | Product Validations |
|---|---|---|---|---|
| S8037 | Necrostatin-1 (Nec-1) | Necrostatin-1 (Nec-1) is a specific RIP1 (RIPK1) inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells. Necrostatin-1 also blocks IDO and suppresses autophagy and apoptosis. |
|
|
| S8465 | GSK872 | GSK'872 is a potent and selective RIP3 kinase inhibitor which binds RIP3 kinase domain with high affinity (IC50=1.8 nM) and inhibits kinase activity with IC50 of 1.3 nM. It has minimal cross-reactivity. |
|
|
| S8641 | Necrostatin 2 racemate (Nec-1s) | Necrostatin 2 racemate (Nec-1s, 7-Cl-O-Nec1, Necrostatin-1 stable, Necrostatin 1S) is a stable variant of Necrostatin-1. This compound is a more specific RIPK1 inhibitor lacking the IDO-targeting effect, with >1000-fold more selective for RIPK1 than for any other kinase out of 485 human kinases. |
|
|
| S9733 | Mito-TEMPO | Mito-TEMPO (MT), a mitochondria-targeted superoxide dismutase mimetic, protects against the early phase of acetaminophen (APAP) hepatotoxicity by inhibiting peroxynitrite formation. Mito-TEMPO treatment inhibits APAP-induced RIP3 kinase expression. |
|
|
| S8642 | GSK'963 | GSK'963 is a chiral small-molecule inhibitor of RIP1 kinase (RIPK1) with an IC50 of 29 nM in FP binding assays. It is >10 000-fold selective for RIP1 over 339 other kinases. |
|
|
| S6511 | RIPA-56 | RIPA-56 is a highly-potent, selective, and metabolically stable RIP1 (RIPK1) inhibitor. |
|
|
| S8484 | GSK2982772 | GSK2982772 is an ATP competitive receptor-interacting protein-1 (RIP1) kinase (RIPK1) inhibitor with the IC50 value of 16 nM. It has exquisite kinase specificity and excellent activity in blocking many TNF-dependent cellular responses. |
|
|
| S8261 | GSK583 | GSK583 is a highly potent and selective inhibitor of RIP2 kinase with IC50 of 5 nM. This compound also inhibits both TNF-α and IL-6 production with IC50 of ~200 nM in explant cultures. |
|
|
| S6078 | ICCB-19 hydrochloride | ICCB-19 hydrochloride is an inhibitor of TNFRSF1A Associated Via Death Domain (TRADD) with IC50 of 1.12 μM and 2.01 μM for protecting Velcade-induced apoptosis in Jurkat cells and protecting RDA in MEFs, respectively. ICCB-19 indirectly inhibits Receptor-interacting serine/threonine-protein kinase 1 (RIPK1). ICCB-19 effectively induces autophagy. |
|
|
| S8775 | HS-1371 | HS-1371 is a potent RIP3 kinase inhibitor with an IC50 of 20.8 nM. It binds to the ATP binding pocket of RIP3 and inhibits ATP binding to prevent RIP3 enzymatic activity in vitro. |
|
|
| S8927 | GSK2983559 (compound 3) | GSK2983559 (compound 3, RIP2 kinase inhibitor 1, RIPK2-IN-1) is a potent inhibitor of receptor interacting protein 2 (RIP2) kinase with good kinase specificity. |
|
|
| S3443 | GSK-843 | GSK-843 (GSK'843) is a selective inhibitor of receptor-interacting protein kinase 3 (RIP3 or RIPK3) that binds to the RIP3 kinase domain with an IC50 of 8.6 nM and effectively inhibits its enzymatic activity with an IC50 of 6.5 nM. |
|
|
| S8787 | GSK'547 | GSK'547 is a highly selective and potent inhibitor of RIP1 (RIPK1) exhibiting a 400-fold improvement in mouse pharmacokinetic oral exposure compared with GSK'963 |
|
|
| S8845 | GSK3145095 | GSK3145095 is a potent and orally active RIP1 kinase inhibitor with IC50 of 6.3 nM with potential antineoplastic and immunomodulatory activities. |
|
|
| S8169 | GSK481 | GSK481 is a RIP1(Receptor Interacting Protein Kinase1, RIPK1) inhibitor. Inhibition of this compound has been shown to hinder cell necrotic death. |
|
|
| E2822 | GSK2983559 active metabolite | GSK2983559 active metabolite is an active metabolite of GSK2983559, also is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043446 A1, compound example 1. | ||
| E2367 | PK68 | PK68 is a potent orally active and specific inhibitor of receptor-interacting kinase 1 (RIPK1) with an IC50 of ~90 nM. | ||
| E5857New | GSK-872 hydrochloride | GSK-872 hydrochloride is an inhibitor of RIPK3, which binds the RIP3 kinase domain with an IC50 of 1.8 nM and inhibits kinase activity with an IC50 of 1.3 nM. It exhibits the potential in alleviating early brain injury by inhibiting neuronal necroptosis and HMGB1-mediated inflammation. | ||
| E0301 | Necrostatin-34 (Nec-34) | Necrostatin-34 (Nec-34) is a small molecule inhibitor of RIPK1 kinase with an IC50 of 0.13 μM in L929 cells. | ||
| E4640 | Oditrasertib | Oditrasertib (DNL-788, SAR 443820) is a first-in-class, selective, orally bioavailable, brain penetrant inhibitor of Receptor-interacting serine/threonine protein kinase 1 (RIPK1). It can be used in research of myotrophic lateral sclerosis and multiple sclerosis. | ||
| E2648 | RIPK1-IN-7 | RIPK1-IN-7 is a potent and selective receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor with a Kd of 4 nM and an enzymatic IC50 of 11 nM. | ||
| E1734 | OD36 | OD36 is an inhibitor of RIPK2 with an IC50 value of 5.3 nM. This compound is a macrocyclic inhibitor with potent binding to the ALK2 kinase ATP pocket. | ||
| S2805 | LY364947 | LY364947 (HTS 466284) is a potent ATP-competitive inhibitor of TGFβR-I with IC50 of 59 nM in a cell-free assay, shows 7-fold selectivity over TGFβR-II. |
|
|
| S9786 | Tuxobertinib (BDTX-189) | BDTX-189 (Tuxobertinib) is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations with Kd of 0.2 nM, 0.76 nM, 13 nM and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. This compound exhibits anticancer activity. |
|
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.